Impel Pharmaceuticals Inc. (IMPL) reported Q2 EPS of ($1.31), $0.31 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.81 million.
Impel Pharmaceuticals Inc. (IMPL) reported Q2 EPS of ($1.31), $0.31 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.81 million.